MX390100B - Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. - Google Patents

Suspension acuosa que contiene nanoparticulas de glucocorticosteroide.

Info

Publication number
MX390100B
MX390100B MX2017014340A MX2017014340A MX390100B MX 390100 B MX390100 B MX 390100B MX 2017014340 A MX2017014340 A MX 2017014340A MX 2017014340 A MX2017014340 A MX 2017014340A MX 390100 B MX390100 B MX 390100B
Authority
MX
Mexico
Prior art keywords
aqueous suspension
suspension containing
nanoparticles
drops
ear
Prior art date
Application number
MX2017014340A
Other languages
English (en)
Other versions
MX2017014340A (es
Inventor
Kazuhiro Kagami
Kenta Kikuchi
Takahiro Tada
Original Assignee
Activus Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activus Pharma Co Ltd filed Critical Activus Pharma Co Ltd
Publication of MX2017014340A publication Critical patent/MX2017014340A/es
Publication of MX390100B publication Critical patent/MX390100B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un objetivo es proporcionar una suspensión acuosa que contiene como componente activo un compuesto glucocorticosteroide. De modo específico, el objetivo es proporcionar una composición farmacéutica de uso práctico que contiene como componente activo un compuesto glucocorticosteroide. La presente invención es proporcionar una suspensión acuosa que contiene nanopartículas de un compuesto glucocorticosteroide y un estabilizante de dispersión, la suspensión acuosa que contiene las nanopartículas con un diámetro medio de partícula de 300 nm o menos y un diámetro de partícula D90 de 450 nm o menos, composiciones farmacéuticas para administraciones parenterales, inyecciones; gotas para los ojos o gotas para los oídos que contienen la suspensión acuosa, de modo más específico gotas para los ojos para tratar o prevenir enfermedades inflamatorias del ojo o gotas para los oídos para tratar o prevenir enfermedades inflamatorias del oído.
MX2017014340A 2015-05-08 2016-05-09 Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. MX390100B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015095610 2015-05-08
PCT/JP2016/063752 WO2016181935A1 (ja) 2015-05-08 2016-05-09 グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤

Publications (2)

Publication Number Publication Date
MX2017014340A MX2017014340A (es) 2018-09-21
MX390100B true MX390100B (es) 2025-03-20

Family

ID=57248091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014340A MX390100B (es) 2015-05-08 2016-05-09 Suspension acuosa que contiene nanoparticulas de glucocorticosteroide.

Country Status (17)

Country Link
US (2) US10588913B2 (es)
EP (1) EP3295943B1 (es)
JP (1) JP6856525B2 (es)
KR (2) KR102268710B1 (es)
CN (1) CN107613985B (es)
AU (1) AU2016262185B2 (es)
CA (1) CA2985171C (es)
ES (1) ES2937023T3 (es)
FI (1) FI3295943T3 (es)
HU (1) HUE061418T2 (es)
IL (1) IL255452B (es)
MX (1) MX390100B (es)
PL (1) PL3295943T3 (es)
PT (1) PT3295943T (es)
RU (1) RU2747803C2 (es)
TW (1) TWI773641B (es)
WO (1) WO2016181935A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582264B (zh) * 2017-03-26 2022-11-11 V·R·斯塔福德 眼睑皮肤状况的处理方法
SG11201912393XA (en) * 2017-06-23 2020-01-30 Salvat Lab Sa An oil-in-water nanoemulsion composition of clobetasol
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
JP2022516099A (ja) 2018-12-27 2022-02-24 サーフィス オフサルミクス，インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
EP3962533A4 (en) 2019-04-30 2023-01-25 The Medical College of Wisconsin, Inc. PLATFORM FOR THROAT ADMINISTRATION AND USES THEREOF
JP7021301B2 (ja) * 2019-07-23 2022-02-16 ニコックス アフサァルミィクス、 インコーポレイテッド 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法
CN112656760B (zh) * 2019-09-27 2022-04-12 武汉科福新药有限责任公司 一种二氟泼尼酯混悬滴眼液及其制备方法
JP7641566B2 (ja) * 2021-04-21 2025-03-07 学校法人近畿大学 超微細化水難溶性薬物及び水溶性薬物を含む点眼剤並びにその製造方法及び使用方法
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途
KR102653853B1 (ko) * 2021-06-21 2024-04-01 가톨릭대학교 산학협력단 약물　전달용 나노서스펜션 및 이의 용도
KR102927998B1 (ko) * 2022-12-09 2026-02-20 가톨릭대학교 산학협력단 약물　전달용 조성물 및 이의 용도
CN116077669B (zh) * 2022-12-15 2024-11-15 中南大学湘雅医院 用于治疗关节痛的糖皮质激素纳米脂质载体、制法及应用
JP2026524248A (ja) * 2023-05-01 2026-07-22 フォルモサ ファーマスーティカルズ インコーポレーテッド 白内障手術の手術合併症を治療する方法
JP2026522788A (ja) * 2023-05-01 2026-07-09 エイマックス セラピューティクス，インコーポレイテッド コルチコステロイドナノ懸濁液及びその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
ZA966579B (en) 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
EP0995435B1 (en) 1997-05-14 2007-04-25 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
JP4167463B2 (ja) * 1997-05-14 2008-10-15 千寿製薬株式会社 再分散性の良い水性懸濁液剤
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
TWI405590B (zh) 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
MY161021A (en) 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
US20110165259A1 (en) 2008-09-19 2011-07-07 Activus Pharma Co., Ltd. Composite organic compound powder for medical use, method for producing same and suspension of same
WO2012051426A2 (en) 2010-10-15 2012-04-19 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
CN103442700B (zh) * 2011-03-24 2016-04-06 利奥制药有限公司 含有脂质纳米颗粒和皮质类固醇或维生素d衍生物的组合物
JP6054380B2 (ja) 2012-05-11 2016-12-27 株式会社アクティバスファーマ 有機化合物ナノ粉体、その製造方法ならびに懸濁液
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects

Also Published As

Publication number Publication date
IL255452A (en) 2018-01-31
KR20180004164A (ko) 2018-01-10
KR102268710B1 (ko) 2021-06-23
PT3295943T (pt) 2023-02-02
MX2017014340A (es) 2018-09-21
JPWO2016181935A1 (ja) 2018-02-22
HUE061418T2 (hu) 2023-06-28
EP3295943A1 (en) 2018-03-21
PL3295943T3 (pl) 2023-05-08
IL255452B (en) 2022-08-01
US20180117064A1 (en) 2018-05-03
CA2985171C (en) 2021-11-02
JP6856525B2 (ja) 2021-04-07
US20200129526A1 (en) 2020-04-30
RU2747803C2 (ru) 2021-05-14
AU2016262185B2 (en) 2021-05-13
US11376262B2 (en) 2022-07-05
TWI773641B (zh) 2022-08-11
RU2017142694A (ru) 2019-06-10
KR102390014B1 (ko) 2022-04-22
RU2017142694A3 (es) 2019-11-11
CN107613985B (zh) 2021-05-25
ES2937023T3 (es) 2023-03-23
AU2016262185A1 (en) 2017-12-21
US10588913B2 (en) 2020-03-17
FI3295943T3 (fi) 2023-03-03
EP3295943B1 (en) 2022-11-30
KR20210076202A (ko) 2021-06-23
WO2016181935A1 (ja) 2016-11-17
BR112017024000A2 (pt) 2018-07-17
CA2985171A1 (en) 2016-11-17
TW201701882A (zh) 2017-01-16
CN107613985A (zh) 2018-01-19
EP3295943A4 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
MX2017014340A (es) Suspension acuosa que contiene nanoparticulas de glucocorticosteroide.
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
AU2018260835A1 (en) Low molecular weight silk compositions and stabilizing silk compostions
CO2017012573A2 (es) Formación de nanopartículas de ciclosporina a/ciclodextrina
ECSP19057713A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cáncer
DOP2016000041A (es) Compuestos derivados de 5,5,7,7-tetrametil-5,7-dihidro-4h-tieno[2,3-c]piran-3-carboxamida que son moduladores del regulador de la conductancia transmembrana de la fibrosis quística (cftr)
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
CY1122500T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων
MX384021B (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
BR112017016093A2 (pt) composição sólida, curativo de ferida, e, método de fabricação de uma composição
AR091237A1 (es) Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
PH12015502587A1 (en) Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
MX2021014049A (es) Compuestos espiro triciclicos.
HK1205461A1 (zh) 用於眼部传输治疗剂的组合物和方法
EA201691194A1 (ru) Стимуляторы ргц
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
MX2019000795A (es) Composiciones de limpieza liquidas con sistema antibacteriano y metodo para su fabricacion.
MX2016005764A (es) Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.
MX2017009699A (es) Composicion de suspension oftalmica.
MX2019010852A (es) Nanoparticulas a base de lipidos con estabilidad mejorada.
CR20170293A (es) Derivados de glucagón con estabilidad mejorada
HK1220173A1 (zh) Ship1调节剂和与其相关的方法
CL2017000120A1 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares